Brief: CNS Pharmaceuticals Announces Activation Of First Clinical Trial Sites In Europe For Ongoing Potentially Pivotal Global Trial Evaluating Berubicin For The Treatment Of GBM

CNS Pharmaceuticals

28/09/2022 14:34

Sept 28 (Reuters) - CNS Pharmaceuticals Inc  CNSP.O :
    * CNS PHARMACEUTICALS ANNOUNCES ACTIVATION OF FIRST CLINICAL
TRIAL
SITES IN EUROPE FOR ONGOING POTENTIALLY PIVOTAL GLOBAL TRIAL
EVALUATING BERUBICIN FOR THE TREATMENT OF GBM
    * CNS PHARMACEUTICALS INC - INTERIM ANALYSIS OF TRIAL WHEN
30-50%
OF SUBJECTS REACH 6 MONTHS IN STUDY

Source text for Eikon:  ID:nPn6qmNzZa 
Further company coverage:  CNSP.O 
 ((Reuters.Briefs@thomsonreuters.com;;))